The present invention relates to a monoclonal antibody specific to porcine circovirus 2 (PCV2) and a method for diagnosing post-weaning multi-systemic wasting syndrome (PMWS) using the same. More specifically, the present invention relates to monoclonal antibodies C4-1 and C4-8 of scFV-human C fusion recombinant protein, which specifically binds to a decoy epitope of porcine circovirus 2, and to a method for diagnosing post-weaning multi-systemic wasting syndrome using the same. The monoclonal antibody of the present invention makes it possible to determine whether an antibody against PCV2 is a neutralizing antibody by a vaccine antigen or an antibody induced by immune decoy.

The present invention relates to improved methods and assays for the detection of AAV neutralizing antibodies in sera. The present invention provides safe, sensitive and high throughput neutralization assays for antibody detection.

Methods and compositions for generating immune responses using adenovirus vectors that allow multiple vaccinations or in combination with other therapy and vaccinations in individuals with preexisting immunity to adenovirus are provided.

The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject.

A new species of circovirus, porcine circovirus type 3 (PCV3), was identified from sows with clinical symptoms normally associated with porcine circovirus type 2 (PCV2) infection and in aborted fetuses. Molecular and serological analyses suggest PCV3 commonly circulates in U.S. swine. The present disclosure provides immunological compositions and methods related to the production and administration of such compositions.

The present invention relates to a composition which includes antibodies against one or more specified virus, bacteria and/or pathogen for use to improve dog health, wherein the composition is administered before 24 hours of age of the dog or between 24 hours and up to 90 days of age of the dog.

Provided are antibodies that specifically bind to Vaccinia Virus B5 antigen (VV B5). In certain embodiments, the anti-VV B5 antibodies are humanized antibodies. Fusion proteins and conjugates comprising such antibodies are also provided. Pharmaceutical compositions comprising the antibodies, fusion proteins and conjugates of the present disclosure are also provided, as are methods of using such compositions, e.g., for therapy, in vivo imaging and/or the like. In certain aspects, provided are methods that comprise administering an antibody, fusion protein or conjugate of the present disclosure to an individual, wherein the individual comprises cells infected with VV, and wherein the antibody, fusion protein or conjugate is targeted to the infected cells by VV B5 antigens expressed on the surface of the infected cells.

The present document is directed to a new poxvirus infecting salmon. The present document further discloses the genomic sequence of this double-stranded DNA virus and the use of this sequence information for detection, diagnosis and/or vaccine development for the virus.

The present invention is directed to mutant parvovirus VP1 unique region polypeptides, compositions comprising such polypeptides, methods of making such compositions, as well as methods for identifying the likely presence of parvovirus-neutralizing antibodies, and methods for assessing the functional immunogenicity of parvovirus vaccines and measuring a correlate of efficacy to assess a treatment for parvovirus infection.

A nanobody directed against begomoviruses is capable of selectively binding to ToLCSDV viral particles, TYLCV particles, and/or other begomoviruses. The nanobody includes an amino acid sequence of SEQ ID NO: 2.